Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Consumer Discretionary · ·
$5.34
▼ $0.04 (-0.7%)
Market data updated: 09/19 04:14 AM
Fundamentals updated: 09/18/2026
News analyzed: 09/19/2026
Market Cap
$472.41M
Day Range
$5.24 - $5.49
52-Week Range
$3.95 - $6.50
Beta
—
Next Earnings
09.11.2026
Support
$4.86
Resistance
$6.32
SRTA is a stock from the Consumer Cyclical sector — Retail, automotive, and leisure — demand rises and falls with economic sentiment and consumers' disposable income.
+3.5% (1Y)
Strengths: 10/27 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 34.3%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$15.72 vs. price $5.34 (-394.4%)
Fair Value
Signal tension
Growth scores strong (68/100), but fair-value analysis scores this stock as relatively expensive (43/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
51
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
68
Quality
58
Value
43
Momentum
24
Risk
40
Sentiment
86
Fundamental
60
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Strata Critical Medical, Inc. has primarily centered on its financial performance and market outlook, particularly after its Q2 2026 earnings report. Analysts have upgraded the stock to "Buy," projecting significant upside potential—up to 47.28%—driven by rising earnings estimates. The company’s earnings call highlighted strong financial momentum, with some investors comparing its growth strategy to layered investment opportunities. Market sentiment remains positive, with shares gaining momentum amid optimistic analyst revisions.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Strata Critical Medical, Inc.. News trend score: 86. Reason: 7 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
15
🎯 Conviction (vs. Emotion)
41
Psychology
37
Fundamentals
60
Technical
24
Valuation
43
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
-9%
Market Narrative
53
Fundamental Reality
41
Narrative Gap
+12
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for SRTA suggests a **neutral-to-cautious sentiment** with no dominant psychological state, as all scores remain below 25. The lack of extreme momentum (-10.9% ROC), moderate volume (1.07x), and neutral RSI (38) indicate neither panic nor euphoria. Herding appears passive, given underperformance relative to peers. The key open question is whether the slight narrative-reality gap (4 points) reflects lingering uncertainty or a delayed reaction to recent developments. The absence of volatility spikes (0.87x ATR) further implies a measured, not frantic, response.
Updated: 09/09/2026, 09:15 AM
👥 What the crowd believes
"Revenue Surges 60%"
"solid earnings estimate revisions"
"boosts 2026 outlook after record Q2 performance driven by transplant services and strategic acquisitions"
"Upgraded to Buy"
📈 12D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The stark contrast in verdicts for SRTA reflects deep methodological divides between investors prioritizing stability and those focused on growth or cyclical timing. Bagehot, Lynch, and Nelson—each with scores above 90—see this stock as a resilient, undervalued opportunity, with Bagehot emphasizing liquidity, Lynch spotting growth potential, and Nelson identifying a favorable cycle position. Meanwhile, Graham’s defensive and enterprising approaches split, with the former approving it as a solid hold but the latter dismissing it as lacking the deep bargain appeal he sought. On the other end, traders like Livermore and Housel reject it outright, with Livermore’s trend-following rule and Housel’s aversion to volatility creating a hard stop, while Marks and Loeb caution against overpaying or underestimating risk. The divergence underscores whether the stock’s strengths—growth, liquidity, or cyclical positioning—outweigh its perceived risks or market inefficiencies.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 96
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 89
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 79
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 69
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 66
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 64
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 62
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 54
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 46
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 44
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 43
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 42
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 41
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 279 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 8 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
20.9%
Operating Margin
-11.3%
Net Margin
21.0%
EBITDA Margin
-7.2%
ROE
14.8%
ROA
12.7%
ROIC
—
EPS
$0.50
Cash
$30.97M
Total Debt
—
Current Ratio
6.38
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$5.34
Estimated Fair Value (DCF)
-$15.72
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-394.4%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
17.9%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 17.9% | $-68.96M | $-63.27M |
| 2 | 14.0% | $-78.63M | $-66.18M |
| 3 | 10.2% | $-86.63M | $-66.90M |
| 4 | 6.3% | $-92.13M | $-65.26M |
| 5 | 2.5% | $-94.43M | $-61.37M |
Base FCF (last actual year)
$-58.51M
Terminal Value
$-1.49B
Present Value of Terminal Value
$-967.79M
Enterprise Value
$-1.29B
Net Debt
$0
Equity Value
$-1.29B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$3.40
Tangible Book Value per Share (Tangible NAV)
$1.75
Sentiment based on basic keywords (not AI) — 7 positive, 12 neutral, 1 negative out of the last 20 articles.
SeekingAlpha · 16.9.2026
Benzinga · 11.9.2026
SeekingAlpha · 10.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
PR Newswire · 24.8.2026
Zacks · 24.8.2026
Zacks · 24.8.2026
Motley Fool · 11.8.2026
Insider Monkey · 11.8.2026
Zacks · 6.8.2026
Yahoo · 6.8.2026
SeekingAlpha · 5.8.2026
Moby · 4.8.2026
Yahoo · 4.8.2026
GuruFocus.com · 4.8.2026
Yahoo · 4.8.2026
Zacks · 4.8.2026
Yahoo · 4.8.2026
GlobeNewswire · 4.8.2026
Strata Critical Medical, Inc. (SRTA) currently has a StockIQ AI score of 51/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
SRTA currently scores 51/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, SRTA's estimated fair value is -$15.72, which is 394.4% below the current price of $5.34. This is one valuation model among several signals in the fair-value category, not a price target.
SRTA's technical score is 24/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 34.3%; Earnings per share (EPS) growth: 242.9%; Net income growth: 251.4%.
Based on the real signals StockIQ computed: Estimated fair value: -$15.72 vs. price $5.34 (-394.4%); Operating margin: -11.3% (negative); ATR: 4.2% of price.
StockIQ has no recorded dividend payment history for SRTA.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 2 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Wunsch Scott M | Tax Withholding in Shares | 8.9.2026 | 5,711 | -5,711 | $5.31 |
| Tomkiel Melissa M. | Tax Withholding in Shares | 8.9.2026 | 29,730 | -29,730 | $5.31 |
| Verdetto Louis R. | Tax Withholding in Shares | 8.9.2026 | 5,697 | -5,697 | $5.31 |
| Cohen Amir | Tax Withholding in Shares | 8.9.2026 | 4,645 | -4,645 | $5.31 |
| Heyburn William A. | Tax Withholding in Shares | 8.9.2026 | 31,671 | -31,671 | $5.31 |
| Love Reginald | Open Market Sale | 10.8.2026 | 5,091 | -5,091 | $5.75 |
| Love Reginald | Open Market Sale | 10.8.2026 | 146,481 | -5,091 | $5.75 |
| Wunsch Scott M | Tax Withholding in Shares | 31.7.2026 | 13,992 | -13,992 | $5.09 |
| Heyburn William A. | Tax Withholding in Shares | 31.7.2026 | 199,209 | -199,209 | $5.09 |
| Tomkiel Melissa M. | Tax Withholding in Shares | 31.7.2026 | 212,309 | -212,309 | $5.09 |
| Cohen Amir | Tax Withholding in Shares | 31.7.2026 | 34,015 | -34,015 | $5.09 |
| Cohen Amir | Tax Withholding in Shares | 31.7.2026 | 181,799 | -34,015 | $5.09 |
| Tomkiel Melissa M. | Tax Withholding in Shares | 31.7.2026 | 2,096,347 | -212,309 | $5.09 |
| Heyburn William A. | Tax Withholding in Shares | 31.7.2026 | 1,710,019 | -199,209 | $5.09 |
| Wunsch Scott M | Tax Withholding in Shares | 31.7.2026 | 668,754 | -13,992 | $5.09 |
| Tomkiel Melissa M. | Grant/Award from Employer | 30.7.2026 | 206,953 | +206,953 | — |
| Tomkiel Melissa M. | Grant/Award from Employer | 30.7.2026 | 208,929 | +208,929 | — |
| Heyburn William A. | Grant/Award from Employer | 30.7.2026 | 179,160 | +179,160 | — |
| Love Reginald | Grant/Award from Employer | 30.7.2026 | 37,675 | +37,675 | — |
| Cohen Amir | Grant/Award from Employer | 30.7.2026 | 27,420 | +27,420 | — |
| Cook William L. III | Grant/Award from Employer | 30.7.2026 | 44,438 | +44,438 | — |
| Wunsch Scott M | Grant/Award from Employer | 30.7.2026 | 57,172 | +57,172 | — |
| Heyburn William A. | Grant/Award from Employer | 30.7.2026 | 181,071 | +181,071 | — |
| Cohen Amir | Grant/Award from Employer | 30.7.2026 | 41,786 | +41,786 | — |
| PHILIP EDWARD M | Grant/Award from Employer | 30.7.2026 | 30,913 | +30,913 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,525,352 shares short as of 2026-08-31 · vs. 4,201,679 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
59.6% of trading volume this week was short selling, vs. 51.5% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology